Mind Medicine (MindMed) Inc. to Post FY2027 Earnings of $0.18 Per Share, HC Wainwright Forecasts (NASDAQ:MNMD)

Mind Medicine (MindMed) Inc. (NASDAQ:MNMDGet Rating) – Equities research analysts at HC Wainwright issued their FY2027 EPS estimates for Mind Medicine (MindMed) in a research note issued to investors on Thursday, January 19th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $0.18 for the year. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($2.33) per share.

A number of other equities research analysts also recently weighed in on the stock. Maxim Group dropped their price target on shares of Mind Medicine (MindMed) from $22.50 to $8.00 in a research report on Monday, November 14th. Royal Bank of Canada began coverage on shares of Mind Medicine (MindMed) in a research note on Wednesday, November 16th. They issued an “outperform” rating on the stock. Canaccord Genuity Group decreased their price objective on shares of Mind Medicine (MindMed) from $22.00 to $18.00 in a research note on Monday, November 21st. EF Hutton Acquisition Co. I began coverage on shares of Mind Medicine (MindMed) in a research note on Friday, December 16th. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, UBS Group began coverage on shares of Mind Medicine (MindMed) in a research note on Thursday, December 15th. They issued a “buy” rating and a $21.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $33.13.

Mind Medicine (MindMed) Trading Up 7.3 %

NASDAQ MNMD opened at $3.54 on Friday. Mind Medicine has a 1-year low of $2.12 and a 1-year high of $22.20. The company has a 50 day moving average of $2.74 and a 200-day moving average of $5.84. The company has a market cap of $133.00 million, a price-to-earnings ratio of -1.50 and a beta of 1.63.

Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02.

Institutional Trading of Mind Medicine (MindMed)

A number of hedge funds and other institutional investors have recently modified their holdings of MNMD. Swiss National Bank grew its stake in shares of Mind Medicine (MindMed) by 23.1% during the first quarter. Swiss National Bank now owns 951,100 shares of the company’s stock worth $1,079,000 after buying an additional 178,300 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Mind Medicine (MindMed) by 12.4% during the first quarter. JPMorgan Chase & Co. now owns 151,310 shares of the company’s stock worth $168,000 after buying an additional 16,666 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Mind Medicine (MindMed) by 1.8% during the first quarter. Bank of New York Mellon Corp now owns 936,388 shares of the company’s stock worth $1,039,000 after buying an additional 16,746 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Mind Medicine (MindMed) by 77.2% in the first quarter. HighTower Advisors LLC now owns 104,975 shares of the company’s stock worth $119,000 after purchasing an additional 45,747 shares during the last quarter. Finally, Penserra Capital Management LLC grew its stake in shares of Mind Medicine (MindMed) by 98.6% in the first quarter. Penserra Capital Management LLC now owns 480,853 shares of the company’s stock worth $442,000 after purchasing an additional 238,737 shares during the last quarter. Institutional investors own 20.44% of the company’s stock.

Mind Medicine (MindMed) Company Profile

(Get Rating)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Featured Articles

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.